Denali Therapeutics Inc
NASDAQ:DNLI
Denali Therapeutics Inc
Revenue
Denali Therapeutics Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Denali Therapeutics Inc
NASDAQ:DNLI
|
Revenue
$330.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Denali Therapeutics Inc
Revenue Breakdown
Breakdown by Geography
Denali Therapeutics Inc
Breakdown by Segments
Denali Therapeutics Inc
Total Revenue:
330.5m
USD
|
Atv:abeta Program License:
288.9m
USD
|
Cns Program License:
25m
USD
|
Ptv:pgrn Collaboration Agreement:
10m
USD
|
Option Research Services:
1.6m
USD
|
See Also
What is Denali Therapeutics Inc's Revenue?
Revenue
330.5m
USD
Based on the financial report for Dec 31, 2023, Denali Therapeutics Inc's Revenue amounts to 330.5m USD.
What is Denali Therapeutics Inc's Revenue growth rate?
Revenue CAGR 5Y
21%
Over the last year, the Revenue growth was 205%. The average annual Revenue growth rates for Denali Therapeutics Inc have been -1% over the past three years , 21% over the past five years .